Pharmacopsychiatry 1997; 30(1): 1-5
DOI: 10.1055/s-2007-979474
Original Paper

© Georg Thieme Verlag Stuttgart · New York

Kava-kava Extract WS 1490 versus Placebo in Anxiety Disorders - A Randomized Placebo-controlled 25-week Outpatient Trial

H.-P. Volz1 , M. Kieser2
  • 1Department of Psychiatry, Jena University, Germany
  • 2Dr. Willmar Schwabe GmbH & Co., Department of Biometry, Karlsruhe, Germany
Further Information

Publication History

Publication Date:
20 April 2007 (online)


101 outpatients suffering from anxiety of non-psychotic origin (DSM-III-R criteria: agoraphobia, specific phobia, generalized anxiety disorder, and adjustment disorder with anxiety) were included in a 25-week multicenter randomized placebo-controlled double-blind trial with WS 1490, a special extract of kava-kava. In the main outcome criterion, the Hamilton Anxiety Scale (HAMA), there was a significant superiority of the test drug starting from week 8 on. WS 1490 was also found to be superior with respect to the secondary outcome variables. HAMA subscores somatic and psychic anxiety, Clinical Global Impression, Self-Report Symptom Inventory - 90 Items revised, and Adjective Mood Scale. Adverse events were rare and distributed evenly in both groups. These results support WS 1490 as a treatment alternative to tricyclic antidepressants and benzodiazepines in anxiety disorders, with proven long-term efficacy and none of the tolerance problems associated with tricyclics and benzodiazepines.